A federal appeals court has temporarily blocked an FDA regulation that permitted mifepristone, an abortion pill, to be mailed directly to patients. Louisiana filed the lawsuit challenging the regulation. The court's pause halts expanded access that the FDA had previously authorized. The ruling freezes the current mail-delivery system pending further legal proceedings. This action affects patients seeking medication abortion across the country, limiting their ability to access mifepristone through the mail. The case remains under litigation, with the appeals court's temporary hold now in effect. The decision reverses years of FDA policy that expanded access to the medication by removing certain in-person requirements and allowing mail delivery. Mifepristone is used in combination with misoprostol to terminate early pregnancies. The regulation had permitted patients to obtain the pill through telehealth appointments rather than visiting clinics in person. This court action represents a significant shift in abortion access policy at the federal level, directly affecting reproductive healthcare options for patients nationwide.